Nido Biosciences announced it will wind down operations in early 2026 after Phase II data fell short of expectations. The Boston‑area startup said the trial outcomes did not support further development of its lead program and the company plans an orderly wind‑down. Nido’s decision highlights the cash and data risks small biotechs face when mid‑stage trials fail to confirm earlier promise. The company said it will work to preserve data and explore potential asset sales or transfers where feasible. Stakeholders including employees, investors and collaborators will monitor next steps; this closure adds to a year of strategic consolidations and program terminations across the sector.